Noom

Noom combines psychology-based behavior change content with human coaching and AI to deliver weight management and chronic condition programs via mobile app. Valued at $3.7B (2021). Revenue ~$400M+. Launched Noom Med with GLP-1 prescribing. Laid off staff in 2023-24 restructuring. Filed for IPO in 2022 but delayed.

Noom's consumer brand strength and psychology-first approach established the D2C digital therapeutic model; its pivot into medical weight management (Noom Med, GLP-1s) shows how DTx companies evolve into clinical service delivery.

noom.com Digital Therapeutics

United Statesprivate

At a glance

Total raised

$637.8M

last round series f

Headcount

1k-5k

approximate · public range

Headquarters

New York

United States

Founded

2008

18 years active

Status

Private

Digital Therapeutics

Latest valuation

$3.7B

Series F · 2021

For subscribers

Subscribe to see the full profile

Including Funding rounds, Bull / Bear thesis, Stock + earnings, Roster changes, Patents, News, and Open roles.

Founding

50% off

/month

94 of 100 spots left

Full

$10

/month

Available once all 100 Founding Member spots are claimed.

Get full access

Already subscribed? Sign in →

Funding history

Total raised

$637.8M

Rounds tracked

Latest stage

Series F

Latest valuation

$3.7B

Date	Stage	Amount	Valuation	Lead investors
May 25, 2021	Series F	$540M	$3.7B	Silver Lake
May 6, 2019	Series E	$58M	—	Sequoia Capital
Mar 1, 2018	Series D	$14M	—	Sampo Holdings
Dec 20, 2016	Series C	—	—	Samsung Ventures
Apr 1, 2015	Series B	$16.1M	—	InterVest
Feb 4, 2014	Series A	$7M	—	RRE Ventures
Aug 1, 2012	Pre-Seed	$2.6M	—	m8 Capital

Founder backgrounds

Artem Petakov

President (former)

A Princeton University graduate (computer science, finance, and theater), Petakov took Daniel Kahneman's psychology of decision-making class — an early thread that connects to Noom's psychology-based health methodology. Before co-founding Noom, he was a software engineer and tech lead on Google Maps, where he led the User-Created Map Content team, and previously co-founded WorkSmart Labs as CTO. In 2020 Fortune named him to its 40 Under 40 in healthcare. He served as Noom's President until March 2024, when he transitioned to Head of Noom Ventures, and has since shifted focus to a new venture, Ez Health, aiming to simplify healthcare navigation.

Saeju Jeong

Executive Chairman

Co-founded Noom in 2008 alongside former Google software engineer Artem Petakov, combining psychology-based behavior change with mobile technology. Born in South Korea to a family of doctors, a background that informed Noom's focus on preventive health. Led the company as CEO for 15 years, raising $657M from Sequoia Capital and Silver Lake, and scaling Noom to unicorn status before transitioning to Executive Chairman in July 2023. Serves on the board of the Foundation of the National Institutes of Health and is a member of the Aspen Institute's Henry Crown Fellowship (2024 class). Also active as an investor with Sequoia Capital and as co-founder of Founders Global, a network for international founders.

AI bull / bear

Bull case

Noom sits at the intersection of two megatrends — the GLP-1 revolution and the shift toward value-based chronic care — and its psychology-first behavior change engine is precisely the moat that pure-play telehealth prescribers lack. With $400M+ in revenue and a recognized consumer brand, Noom has the distribution to acquire obesity patients at scale without relying on slow-moving employer or payer gatekeepers. The Noom Med launch transforms the platform from a weight-loss app into a clinical service: GLP-1 prescribing combined with coaching creates a retention flywheel competitors cannot easily replicate. Medication gets patients results; the behavior change program builds habits that persist when doses taper. Silver Lake's $540M Series F at a $3.7B valuation signals institutional conviction. The 2023-24 restructuring, while painful, likely stripped out bloat from the pandemic-era hiring surge, yielding a leaner organization with a clear medical roadmap. If Noom demonstrates superior GLP-1 adherence and long-term weight maintenance versus prescription-only rivals, payer interest and a re-filed IPO become inevitable.

Bear case

Noom's pivot into GLP-1 prescribing is less a strategic evolution than a defensive scramble into an already crowded field where it holds no structural advantage. WeightWatchers, Ro, Hims & Hers, and a growing army of telehealth startups now offer near-identical medication-plus-coaching bundles, eroding the differentiation that once justified Noom's premium pricing. The 2023-24 layoffs and the shelved 2022 IPO point to a company that over-hired during the pandemic demand spike and is now managing contraction, not growth. At a $3.7B valuation — roughly 9x revenue — Noom is priced for acceleration, yet the D2C weight-loss market is notorious for churn, and customer acquisition costs rise as competitors saturate the same digital ad channels. The psychology-based curriculum, while genuinely evidence-backed, faces an existential question: when GLP-1s suppress appetite pharmacologically, does the behavioral layer still command a premium, or does it become a commoditized add-on? Without exclusive payer contracts or proprietary clinical outcomes data, Noom risks being outspent and outmaneuvered by larger, better-capitalized entrants.

Generated by deepseek-v4-pro · May 2, 2026Refreshes quarterly · see disclosures

In the news

Noom · last 30 days

No articles ingested yet for Noom. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.

Watch

Leadership

Saeju Jeong

Executive Chairman

Artem Petakov

President (former)

Geoff Cook

Chief Executive Officer

—

Adam Fawer

Chief Operating Officer / Chief Financial Officer

—

Aaron Severs

Chief Product Officer

—

Peter Scherr

Chief Marketing Officer

—

Dr. Adonis Saremi

Chief Medical Officer

—

Products

Noom Weight
Noom Weight is a psychology-based weight management program delivered via mobile app. It combines daily interactive lessons on behavior change, a color-coded food logging system (green, yellow, orange), step tracking, and optional 1:1 human coaching to help users build sustainable healthy habits. Unlike calorie-counting apps, Noom focuses on the psychological drivers behind eating choices, aiming for long-term habit change rather than quick fixes. Members set personalized goals and receive tailored feedback through the app's AI and coach support.
Noom Med
Noom Med is a comprehensive weight-loss program that pairs prescription GLP-1 medications (such as Wegovy, Zepbound, and Ozempic) with Noom's behavior change framework. Members work with licensed clinicians who prescribe and manage medications when clinically appropriate, while also receiving Noom's psychology-based coaching, food tracking, and habit-building tools. The program is designed to maximize medication effectiveness through lifestyle change and to help members sustain weight loss long-term, potentially without medication.
Noom Mood
Noom Mood is a mental wellness program that applies the same psychology-based behavior change methodology to stress reduction and emotional well-being. The program delivers daily lessons, mood tracking tools, and cognitive reframing exercises to help users understand the connection between thoughts, feelings, and behaviors. It provides personalized content and optional coaching to help users build resilience, manage anxiety, and develop healthier emotional patterns, similar to how Noom Weight approaches eating habits.
Noom GLP-1Rx Program
Noom GLP-1Rx is a medication-focused program offering access to GLP-1 weight-loss drugs (including brand-name and compounded options) integrated with Noom's habit-change methodology. It includes a specialized GLP-1 Companion feature within the app that helps users manage side effects, track progress, and optimize their medication response. The program offers multiple tiers including standard GLP-1Rx and a Microdose GLP-1Rx option designed to minimize side effects while maintaining weight-loss efficacy.

Open roles

We don't have a live feed for this company's ATS. Their careers page has every open role.

View all careers ↗